布洛芬API 市场- 按类型（标准布洛芬、高效布洛芬）、应用（头痛、关节炎、发烧、牙痛）、最终用途（製药和生物製药公司、CDMO）、全球预测（2024 - 2032 ）

由于布洛芬广泛应用于用于缓解疼痛和发烧的非处方非处方药中，2024 年至 2032 年间，全球布洛芬 API 市场的复合年增长率将超过 3.7%。随着越来越多的消费者寻求常见疾病的可行解决方案，非处方药中对布洛芬的需求持续成长。这种趋势得到了人们对自我药疗的偏好以及无需处方即可购买此类药物的便利性的支持。

据工业和资讯化部工信部称，2022年12月，中国布洛芬和对乙酰氨基酚的日产量自12月初以来翻了两番。这一增长是政府和药品製造商加大努力的结果，以确保感冒和发烧药物的充足供应，以满足不断增长的市场需求。

製药公司正在透过配方和输送系统创新来利用这一需求，提高含布洛芬产品在全球市场的吸引力和有效性。

整个布洛芬 API 市场根据类型、应用、最终用途和地区进行分类。

预测期内，标准布洛芬产业将实现大幅复合年增长率成长。标准布洛芬配方可满足广泛的疼痛缓解需求，从日常疼痛到更严重的病症。这种多功能性使布洛芬成为全球药物製剂的主要成分，带来了持续的需求。此外，其既定的安全性和监管批准增强了其吸引力，确保在医疗保健环境中广泛采用。随着製药公司不断创新新配方和剂型，对布洛芬 API 的需求持续成长，反映了其在疼痛管理解决方案中不可或缺的角色。

到 2032 年，由于布洛芬在治疗头痛和偏头痛方面的有效性，头痛领域将占据相当大的市场份额。随着越来越多的人寻求可靠地缓解这些常见疾病，含有布洛芬的药物製剂因其快速作用和效力而越来越受到青睐。布洛芬作为非处方药的可近性刺激了其在这一领域的需求，使消费者能够方便地处理偶尔的头痛。此外，针对缓解头痛的改进给药系统和配方的持续研究继续扩大布洛芬 API 的市场，有效满足不同患者的需求。

从2024年到2032年，北美布洛芬原料药市场将录得令人印象深刻的复合年增长率。中国、印度和日本等国家的经济发展和医疗保健支出的增加正在扩大药品（包括止痛药）的取得范围。都市化进程的不断加速和生活方式的改变导致需要疼痛管理的疾病发生率更高，从而推动了布洛芬原料药产业的发展。此外，促进医疗保健基础设施发展和改善医疗保健可近性的政府措施刺激了布洛芬原料药的需求。欧洲不断发展的监管环境透过促进药品製造商更容易进入市场和合规性来支持市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 疼痛状况的盛行率不断增加
    • 对非处方药 (OTC) 的需求不断增长
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 对布洛芬副作用的担忧
    • 替代产品的可用性
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 标准布洛芬
• 高效布洛芬

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 头痛
• 关节炎
• 发烧
• 牙齿疼痛
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 製药及生物製药公司
• CDMO 的

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• BASF Corporation
• Dr. Reddy's Laboratories Ltd
• Granules India Limited
• IOL Chemicals and Pharmaceuticals Limited
• Octavius Pharma Pvt. Ltd
• SI Group, Inc.
• Solara Active Pharma Sciences Limited
• Strides Pharma Science Limited
• Rochem International Inc.
• Teva Pharmaceutical Industries Ltd.

Global Ibuprofen API Market will register over 3.7% CAGR between 2024 and 2032, owing to its widespread inclusion in over-the-counter OTC medications used for pain and fever relief. As more consumers seek accessible solutions for common ailments, the demand for Ibuprofen in OTC products continues to grow. This trend is supported by a preference for self-medication and the convenience of purchasing such medications without prescriptions.

Quoting an instance, in December 2022, China daily production of ibuprofen and acetaminophen quadrupled since early December, according to the Ministry of Industry and Information Technology MIIT. This increase is a result of intensified efforts by the government and drug manufacturers to ensure an adequate supply of cold and fever-reducing medications in response to surging market demand.

Pharmaceutical companies are capitalizing on this demand by innovating in formulations and delivery systems, improving the appeal and effectiveness of Ibuprofen-containing products in the global market.

The overall Ibuprofen API market is classified based on type, application, end-use, and region.

During the forecast period, the standard ibuprofen sector will achieve substantial CAGR growth. Standard Ibuprofen formulations cater to a broad spectrum of pain relief needs, ranging from everyday aches to more acute conditions. This versatility makes Ibuprofen a staple in pharmaceutical formulations globally, ushering in consistent demand. Additionally, its established safety profile and regulatory approvals bolster its appeal, ensuring widespread adoption across healthcare settings. As pharmaceutical companies innovate with new formulations and dosage forms, the demand for Ibuprofen API continues to grow, reflecting its integral role in pain management solutions.

By 2032, the headache sector will hold a considerable ibuprofen API market share because of its effectiveness in managing headaches and migraines. As more individuals seek reliable relief from these common ailments, pharmaceutical formulations containing Ibuprofen are increasingly preferred for their rapid action and potency. The accessibility of Ibuprofen as an OTC medication fuels its demand in this segment, allowing consumers to manage occasional headaches conveniently. Moreover, ongoing research into improved delivery systems and formulations tailored to headache relief continues to expand the market for Ibuprofen API, meeting diverse patient needs effectively.

From 2024 to 2032, the North America ibuprofen API market will record an impressive CAGR. Economic development and increasing healthcare expenditures across countries like China, India, and Japan are expanding access to pharmaceuticals, including pain relief medications. Rising urbanization and changing lifestyles contribute to higher incidences of conditions requiring pain management, boosting the ibuprofen API industry. Moreover, governmental initiatives promoting healthcare infrastructure development and improving healthcare access stimulate ibuprofen API demand. Europe's evolving regulatory environment supports market expansion by facilitating easier market entry and compliance for pharmaceutical manufacturers.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of pain conditions
    • 3.2.1.2 Rising demand for over the counter (OTC) medications
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Concerns about the side effects of Ibuprofen
    • 3.2.2.2 Availability of substitute products
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Standard ibuprofen
• 5.3 High potency ibuprofen

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Headache
• 6.3 Arthritis
• 6.4 Fever
• 6.5 Dental pain
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biopharmaceutical companies
• 7.3 CDMO's

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 BASF Corporation
• 9.2 Dr. Reddy's Laboratories Ltd
• 9.3 Granules India Limited
• 9.4 IOL Chemicals and Pharmaceuticals Limited
• 9.5 Octavius Pharma Pvt. Ltd
• 9.6 SI Group, Inc.
• 9.7 Solara Active Pharma Sciences Limited
• 9.8 Strides Pharma Science Limited
• 9.9 Rochem International Inc.
• 9.10 Teva Pharmaceutical Industries Ltd.